Ultomiris approved in the US for adults with generalised myasthenia gravis
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks
This facility will design & develop instruments, perform product reliability performance testing and verification
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Subscribe To Our Newsletter & Stay Updated